Intermittent Hypoxic-Hyperoxic Exposures Effects in Patients with Metabolic Syndrome: Correction of Cardiovascular and Metabolic Profile.

The aim of this study was to evaluate efficacy and applicability of the “intermittent hypoxic-hyperoxic exposures at rest” (IHHE) protocol as an adjuvant method for metabolic syndrome (MS) cardiometabolic components. A prospective, single-center, randomized controlled clinical study was conducted on 65 patients with MS subject to optimal pharmacotherapy, who were randomly allocated to IHHE or control (CON) groups. The IHHE group completed a 3-week, 5 days/week program of IHHE, each treatment session lasting for 45 min.

[The prevalence of liver and gallbladder pathologies in overweight and obese patients].

This paper reports data on the prevalence of liver and gallbladder pathologies in ovenrweight and obese patients based on the examination of 1506 subjects (684 men, 820 women) aged 25-65 years. Changes in the liver and gall bladder constituted principal pathology of the gastrointestinal tract associated with excessive body mass and obesity. Body mass index (BMI) positively correlated with triglyceride, VLDLP and HDLP cholesterol levels (p = 0.

[The scope of clinical applications of noninvasive methods for the assessment of liver fibrosis results of orginial studies in a multi-field hospital].

Potential and limitations of non-invasive methods for the evaluation of hepatic fibrosis are discussed (hepatic elastography, fibrotest, ultrasound dopplerography of portal vessels). Each non-invasive method was assessed in terms of threshold values it provides for the characteristic of successive stages ofhepatic fibrosis. The data obtained were used to develop the optimal algorithm for the diagnosis of hepatic fibrosis in patients with chronic viral liver infection.

[The use of hepatoprotector LiverPro in combined therapy of chronic viral hepatitis C].

We analysed clinical characteristics, laboratory findings, nature and frequency of side effects, and positive virologic response rate in 20 patients with chronic viral hepatitis C (HCV) given combined antiviral therapy with PEG-Intron, ribavirin, and LiverPro hepatoprotector (Santegra, USA, two capsules twice daily) during 3 months. The results were compared with those obtained in the control group of HCV patients receiving the same treatment excepting the hepatoprotector. Clinical manifestations of HCV in the former group disappeared 7-10 days earlier than in control.